Organisation paid for research Program year 2025 Source: CMS Open Payments

Praetorian Pharmaceutical Research, LLC

Neither a doctor nor a teaching hospital

Research payments

$1,326,470

290 payments

Through program year 2025, Praetorian Pharmaceutical Research, LLC is reported as receiving $1,326,470 in research payments, across 290 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$833,261	174
2024	Research	$455,570	93
2023	Research	$37,640	23

Breakdown

Who paid Research payments · program years 2023–2025

Teva Pharmaceuticals USA, Inc. $942,103 148 payments
BioNTech SE $384,368 142 payments

Studies the money was for Research payments · program years 2023–2025

A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma $857,195 122 payments
Bnt331-01 $384,368 142 payments
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy $83,816 16 payments
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma $1,091 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.